James Hardie Industries plc

Condensed Consolidated Financial Statements

as of and for the Three and Six Months Ended 30 September 2024

| | Page |
|--|------------|
| Report of Independent Registered Public Accounting Firm | <u>F-3</u> |
| Condensed Consolidated Balance Sheets as of 30 September 2024 and 31 March 2024 | <u>F-4</u> |
| Condensed Consolidated Statements of Operations and Comprehensive Income for the Three | F F |
| and Six Months Ended 30 September 2024 and 2023 | <u>F-5</u> |
| Condensed Consolidated Statements of Cash Flows for the Six Months Ended 30 September | FO |
| 2024 and 2023 | <u>F-6</u> |
| Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three and | F 7 |
| Six Months Ended 30 September 2024 and 2023 | <u>F-7</u> |
| Notes to Condensed Consolidated Financial Statements | <u>F-9</u> |

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of James Hardie Industries plc

Results of Review of Interim Financial Statements

We have reviewed the accompanying condensed consolidated balance sheet of James Hardie Industries plc ("the Company") as of 30 September 2024, the related condensed consolidated statements of operations and comprehensive income for the three and six-month periods ended 30 September 2024 and 2023, the condensed consolidated statements of cash flows for the six-month periods ended 30 September 2024 and 2023, the condensed consolidated statements of changes in shareholders' equity for the three and six-month periods ended 30 September 2024 and 2023, and the related notes (collectively referred to as the "condensed consolidated interim financial statements"). Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated interim financial statements for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of 31 March 2024, the related consolidated statements of operations and comprehensive income, cash flows and changes in shareholders' equity for the year then ended, and the related notes (not presented herein); and in our report dated 20 May 2024, we expressed an unqualified audit opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of 31 March 2024, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

Basis for Review Results

These financial statements are the responsibility of the Company's management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the SEC and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial statements consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

/s/ Ernst & Young LLP Irvine, California 13 November 2024

James Hardie Industries plc Condensed Consolidated Balance Sheets

| (Millions of US dollars) | (U 30 \$ | naudited) September 2024 | | 31 March 2024 |
|--|-------------|--------------------------------|----|------------------|
| Assets | | 2024 | | 2021 |
| Current assets: | | | | |
| Cash and cash equivalents | \$ | 368.1 | \$ | 365.0 |
| | Ψ | 5.0 | Ψ | 5.0 |
| Restricted cash and cash equivalents | | 12.7 | | 45.8 |
| Restricted cash and cash equivalents - Asbestos | | 194.1 | | 178.4 |
| Restricted short-term investments - Asbestos | | 346.8 | | 366.1 |
| Accounts and other receivables, net | | 340.8 | | 337.8 |
| Inventories | | 83.7 | | 68.2 |
| Prepaid expenses and other current assets | | 60.6 | | |
| Assets held for sale | | 5.5 | | 55.4 |
| Insurance receivable - Asbestos | | | | 5.1 |
| Workers' compensation - Asbestos | | 1.7 | | 1.6 |
| Total current assets | | 1,450.9 | | 1,428.4 |
| Property, plant and equipment, net | | 2,117.0 | | 2,037.8 |
| Operating lease right-of-use-assets | | 69.4 | | 60.9 |
| Goodwill | | 199.5 | | 192.6 |
| Intangible assets, net | | 152.0 | | 149.2 |
| Insurance receivable - Asbestos | | 25.8 | | 26.4 |
| Workers' compensation - Asbestos | | 14.5 | | 13.6 |
| Deferred income taxes | | 632.1 | | 690.4 |
| Deferred income taxes - Asbestos | | 291.2 | | 294.0 |
| Other assets | | 20.9 | | 19.3 |
| Total assets | \$ | 4,973.3 | \$ | 4,912.6 |
| Liabilities and Shareholders' Equity | | | | |
| Current liabilities: | | | | |
| Accounts payable and accrued liabilities | \$ | 412.0 | \$ | 463.3 |
| Accrued payroll and employee benefits | | 105.5 | | 143.3 |
| Operating lease liabilities | | 21.2 | | 19.0 |
| Long-term debt, current portion | | 7.5 | | 7.5 |
| Accrued product warranties | | 6.2 | | 7.3 |
| Income taxes payable | | 1.5 | | 13.0 |
| Asbestos liability | | 124.2 | | 116.7 |
| Workers' compensation - Asbestos | | 1.7 | | 1.6 |
| Other liabilities | | 39.3 | | 26.0 |
| Total current liabilities | - | 719.1 | | 797.7 |
| Long-term debt | | 1,127.8 | | 1,115.1 |
| Deferred income taxes | | 116.9 | | 107.5 |
| Operating lease liabilities | | 65.0 | | 59.4 |
| Accrued product warranties | | 28.6 | | 28.9 |
| Asbestos liability | | 866.8 | | 873.0 |
| Workers' compensation - Asbestos | | 14.5 | | 13.6 |
| | | 57.8 | | 58.5 |
| Other liabilities | | | | |
| Total liabilities | | 2,996.5 | | 3,053.7 |
| Commitments and contingencies (Note 8) | | | | |
| Shareholders' equity: | | | | |
| Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 429,439,842 shares issued and outstanding at 30 September 2024 and 433,784,634 shares issued and outstanding at 31 March 2024 | | 221.9 | | 224.7 |
| Additional paid-in capital | | 264.1 | | 256.5 |
| Retained earnings | | 1,540.4 | | 1,446.0 |
| Accumulated other comprehensive loss | _ | (49.6) | | (68.3) |
| Total shareholders' equity | | 1,976.8 | | 1,858.9 |
| Total liabilities and shareholders' equity | \$ | 4,973.3 | \$ | 4,912.6 |

James Hardie Industries plc Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

| | | Three Ended 30 | | Six Mo Ended 30 S | |
|---|------|-------------------|-------------|----------------------|---------------|
| (Millions of US dollars, except per share data) | | 2024 | 2023 | 2024 | 2023 |
| Net sales | \$ | 960.8 | \$ 998.8 | \$ 1,952.7 | \$ 1,953.1 |
| Cost of goods sold | | 587.9 | 595.2 | 1,182.9 | 1,176.1 |
| Gross profit | | 372.9 | 403.6 | 769.8 | 777.0 |
| Selling, general and administrative expenses | | 149.9 | 152.8 | 299.7 | 281.7 |
| Research and development expenses | | 12.8 | 11.1 | 24.6 | 21.8 |
| Restructuring expenses | | 57.3 | 20.1 | 57.3 | 20.1 |
| Asbestos adjustments | | 0.6 | (3.8) | 0.5 | (3.9) |
| Operating income | | 152.3 | 223.4 | 387.7 | 457.3 |
| Interest, net | | 1.9 | 4.5 | 3.6 | 10.3 |
| Other income, net | | _ | (1.9) | (0.2) | (2.2) |
| Income before income taxes | | 150.4 | 220.8 | 384.3 | 449.2 |
| Income tax expense | | 67.0 | 69.1 | 145.6 | 139.7 |
| Net income | \$ | 83.4 | \$ 151.7 | \$ 238.7 | \$ 309.5 |
| Income per share: | | | | | |
| Basic | \$ | 0.19 | \$ 0.35 | \$ 0.55 | \$ 0.70 |
| Diluted | \$ | 0.19 | \$ 0.34 | \$ 0.55 | \$ 0.70 |
| Weighted average common shares outstanding (Million | ns): | | | | |
| Basic | | 430.8 | 439.6 | 432.0 | 440.7 |
| Diluted | | 432.3 | 440.8 | 433.4 | 441.8 |
| Comprehensive income, net of tax: | | | | | |
| Net income | \$ | 83.4 | \$ 151.7 | \$ 238.7 | \$ 309.5 |
| Currency translation adjustments | | 16.7 | (15.8) | 10.3 | (22.8) |
| Cash flow hedges | | _ | _ | (0.1) | _ |
| Reclassification of other comprehensive income | | 8.5 | | 8.5 | |
| Comprehensive income | \$ | 108.6 | \$ 135.9 | \$ 257.4 | \$ 286.7 |

James Hardie Industries plc Condensed Consolidated Statements of Cash Flows (Unaudited)

| Cash Elows From Operating Activities V V Adjustments to reconcile nel income to net cash provided by operating activities: V V Depreciation and amortization 100.7 90.04 Lease expense 105.5 12.8 Defered income taxes 12.3 12.3 Asbestos adjustments 10.5 (3.9) Gain on sale of find - (2.0) Other, net 16.6 18.9 Changes in operating assets and liabilities: (11.7) (3.13) Counts and other reacivables (17.0) (13.0) Propale dependenting ossets and liabilities: (11.7) (3.13) Counts payable and accrued liabilities: (11.7) (3.13) Counts payable and accrued liabilities (11.7) (3.13) Counts payable and accrued liabilities (11.7) (3.13) Inventories (3.13) (4.2) Operating lease assets and liabilities: (11.7) (3.13) Counts payable and accrued liabilities (11.7) (3.13) Colins and handing occts paid: Abbestos (6.04) | (Millions of US dollars) | Six | Months Ende | ed 30 | September 2023 |
|--|--|----------|-------------|----------|-------------------|
| Adjustments to reconcile net income to net cash provided by operating activities: 99.11 90.4 Lease expense 16.5 12.8 Defered income taxes 72.2 44.1 Stock-based compensation 12.3 12.3 Absences adjustments 0.5 (3.9) Gain on sale of land - (2.0) Other, net 40.2 20.1 Changes in operating assets and liabilities: (31.3) 42.9 Changes in operating assets and liabilities, net (17.4) (31.6) Operating lease assets and liabilities. (17.4) (31.6) Cash and sand accrued liabilities (17.4) (31.6) Insurance reconsuble - Absetos (60.4) (60.3) Income taxes payable and accrued liabilities (11.7) (53.8) Cash Teoren Investing Activities (80.4) (11.7) Note cash provided by operating activities (80.4) (11.7) Technes Tom Investing Activities (80.4) (11.7) Proceeds from sale of property, plant and equipment (82.5) (82.5) Proceeds from sale of property, plant and equipment (12.9) (80.0) Proceeds from insecting Activities (80.4) (80.5) Proceeds from insecting Activities (82.9) (22.1) | Cash Flows From Operating Activities | | | | |
| Depreciation and amortization 101.7 90.4 Lease expense 16.5 12.8 Deferred income taxes 72.2 49.1 Stock-based compensation 12.3 12.3 Stock-based compensation 0.5 (3.9) Gain on sale of land - (2.0) Non-cash restructuring expenses 40.2 20.1 Obter, net 61.5 18.9 Changes in operating assets and liabilities, net (17.4) (13.0) Operating lease assets and liabilities, net (17.4) (13.0) Operating lease assets and liabilities, net (17.7) (13.0) Prepaid expenses and other reselvable (11.7) (13.8) Claims and handling costs paid - Asbestos (11.7) (16.8) Claims and handling costs paid - Asbestos (11.7) (16.8) Other accuel liabilities (9.8) (11.4) Net cash provided by operating activities (9.8) (11.4) Claims and handling costs paid - Asbestos (9.6) (9.7) Other accuel liabilities (9.8) (11.4) <td>Net income</td> <td>\$</td> <td>238.7</td> <td>\$</td> <td>309.5</td> | Net income | \$ | 238.7 | \$ | 309.5 |
| Lesse expense 16.5 12.8 Deferred income taxes 72.2 49.1 Stock-based compensation 12.3 12.3 Asbestos adjustments 0.5 (3.9) Gain on sale of land - (2.0) Other, net 66.6 18.9 Changes in operating assets and liabilities, net (17.0) (13.0) 42.0 Operating lasse assets and liabilities, net (17.0) (13.0) 42.9 Operating lease assets and liabilities, net (17.7) (13.0) 42.9 Operating lease assets and liabilities, net (17.7) (13.0) 42.9 Operating lease assets and liabilities (11.7) (53.8) (11.7) (53.8) Claims and handing costs paid - Asbestos (21.1) (23.8) (11.1) (16.8) Income taxes payable (11.7) (16.8) (11.7) (16.8) Claims and handing costs paid - Asbestos (60.4) (60.3) (11.1) (16.8) Purchase of roporty, plant and equipment - - 4.1 Capitalized interest (| Adjustments to reconcile net income to net cash provided by operating activities: | | | | |
| Deferred income taxes72.249.1Stlock-based compensation12.312.3Stlock-based compensation12.312.3Absetos adjustments0.5(3.9)Gain on sale of land-(2.0.1)Non-cash restructuring expenses40.220.1Oher, net16.518.9Changes in operating assets and liabilities.(31.3)42.9Accounts and other receivables(17.0)(13.0)Prepaid expenses and other assets(17.7)(13.0)Prepaid expenses and other assets(11.7)53.8Cash and anding costs paid - Asbestos(60.3)(11.7)Income taxes payable(11.7)(16.8)Net cash provided by operating activities9.8(11.4)Net cash provided by operating activities9.8(22.2)Proceeds from sale of property, plant and equipment-4.1Cash Elows From Investing Activities9.4(60.2)Proceeds from restricted investments - Asbestos(94.4)(60.2)Proceeds from restricted investments - Asbestos(94.6)(7.7)Proceeds from restricted investments - Asbestos(94.6)(94.7)Proceeds from restricted investments - Asbestos(94.6)(94.7)< | Depreciation and amortization | | | | |
| Stock-based compensation 12.3 12.3 12.3 Asbestos adjustments 0.5 (3.9) Gain on sale of Ind - (2.0) Non-cash restructuring expenses 40.2 20.1) Other, nt 16.6 18.9 Changes in operating assets and liabilities: (11.0) (13.0) Accounts and other receivables (11.7) (13.0) Operating lease assets and liabilities, net (11.7) (13.0) Insurance receivable - Asbestos (11.7) (13.0) Claims and handing costs paid - Asbestos (11.7) (16.8) Claims and handing costs paid - Asbestos (60.4) (60.3) Income laxes payable (11.7) (16.8) Other accured liabilities (11.7) (16.8) Purchases of rosperty, plant and equipment - 4.1 Cash Insurance received by operating activities (225.2) \$ (225.2) Purchases of rosperty, plant and equipment - - 4.1 Capitalized interest (12.8) (12.8) (12.9) Purchased of restri | Lease expense | | | | |
| Asbestos adjustments 0.5 (3.9) Gain on sale of land — (2.0) Other, net 16.6 18.9 Changes in operating assets and liabilities: (14.0) Accounts and other receivables (17.0) (13.3) (42.9) Operating lease assets and liabilities, net (17.0) (13.0) (17.0) (13.0) Operating lease assets and liabilities, net (17.7) (16.8) (17.7) (16.8) Calains and handling costs paid - Asbestos (21.1) (23.8) (11.7) (16.8) Clains and handling costs paid - Asbestos (11.7) (16.8) (11.7) (16.8) Clains and handling costs paid - Asbestos (11.7) (16.8) (11.7) (16.8) Clains and handling costs paid - Asbestos (16.4) (16.0) (11.7) (16.8) Clains and handling costs paid - Asbestos (11.7) (16.8) (11.7) (16.8) Clains and handling costs paid - Asbestos (11.7) (16.8) (11.4) (11.7) (16.8) (11.1) (16.8) (11.2) | Deferred income taxes | | | | |
| Gain on sale of land (2.0) Non-cash restructuring expenses 40.2 20.1 Other, net 16.6 18.9 Changes in operating assets and liabilities: 22.8 (14.0) Inventories (2.1) (31.3) 42.9 Operating lesse assets and liabilities, net (17.4) (31.6) (31.7) Insurance receivable - Asbestos 2.1 2.3 Accounts payable and accrued liabilities (11.7) (58.8) Claims and handling costs paid - Asbestos (60.4) (60.3) (11.7) (58.8) Claims and handling costs paid - Asbestos (60.4) (60.3) (11.7) (58.8) Chair accrued liabilities (11.7) (58.8) (21.2) (22.6) (22.2) Other accrued liabilities (11.7) (58.8) (11.7) (58.8) (11.7) (58.8) Chair accrued liabilities (11.7) (58.8) (22.2) \$ (22.2) \$ (22.2) \$ (22.2) \$ (22.8) \$ (23.8) \$ (45.9) <td< td=""><td></td><td></td><td></td><td></td><td></td></td<> | | | | | |
| Non-cash restructuring expenses 40.2 20.1 Other, net 16.6 18.9 Changes in operating assets and liabilities. 22.8 (14.0) Inventories (31.3) 42.9 Operating lease assets and liabilities, net (17.0) (31.0) Prepaid expenses and other assets (17.0) (31.0) Insurance receivable - Asbestos 21 2.3 Accounts payable and accrued liabilities (11.7) 53.8 Claims and handling costs paid - Asbestos (00.4) (00.3) Income taxes payable (11.7) (11.7) Other accrued liabilities (11.7) (11.4) Tocasts provided by operating activities (11.7) (11.4) Purchases of property, plant and equipment (12.8) (22.52) (22.52) Proceeds from restricted investments - Asbestos (12.8) (20.4) (20.4) Proceeds from restricted investments - Asbestos (12.8) (20.4) (20.4) Proceeds from restricted investments - Asbestos (14.9) (12.13) Proceeds from restricted investments - Asbestos | • | | 0.5 | | . , |
| Other, net 16.6 18.9 Changes in operating assets and liabilities: 22.8 (14.0) Accounts and other receivables (17.0) (13.0) Operating lease assets and liabilities; net (17.0) (13.0) Prepaid expenses and other receivables (17.0) (13.0) Prepaid expenses and other reseivables (17.1) (53.8) Claims and handling costs paid - Asbestos (11.7) (53.8) Claims and handling costs paid - Asbestos (60.4) (60.3) Other accrued liabilities (11.7) (16.8) Other accrued liabilities (9.8) (11.4) Not cash provided by operating activities \$ 44.90.1 (41.8) Purchases of property, plant and equipment - - Proceeds from restricted investments - Asbestos (98.4) (60.5) Proceeds from restricted investments - Asbestos (98.4) (60.5) Proceeds from restricted investments - Asbestos (98.4) (21.2) Cash Flows From Financing Activities \$ (241.4) (241.4) (241.9) Shares repurchased (14.9) | | | - | | |
| Changes in operating assets and liabilities: 22.8 (14.0) Accounts and other receivables (21.3) 42.9 Operating lease assets and liabilities, net (17.0) (13.0) Propaid expenses and other assets (17.1) (21.6) Insurance receivable - Asbestos 2.1 2.3 Accounts payable and accrued liabilities (11.7) 53.8 Claims and handling costs paid - Asbestos (60.4) (60.3) Income taxes payable (11.7) (61.8) Other accrued liabilities (9.8) (11.4) Net cash provided by operating activities (9.8) (11.4) Cash Flows From Investing Activities (9.8) (225.2) \$ (223.6) Proceeds from sale of property, plant and equipment - 4.1 (23.6) (80.0) (60.5) Proceeds from restricted investments - Asbestos (98.4) (60.5) (60.5) (21.2) (24.9) (24.9) (24.9) (24.9) (24.9) (24.9) (24.9) (24.9) (24.9) (24.9) (21.2) (24.9) (24.9) (21.2) (21.2) (21.2) (21.2) (21.2) (| | | | | |
| Accounts and other receivables 22.8 (14.0) Inventories (31.3) 42.9 Operating lease assets and liabilities, net (17.0) (13.0) Prepaid expenses and other assets (17.4) (31.6) Insurance receivable - Asbestos 2.1 2.3 Accounts payable and accrued liabilities (11.7) (53.8) Claims and handling costs paid - Asbestos (60.4) (60.3) Income taxes payable (11.7) (16.8) Other accrued liabilities (11.7) (16.8) Proceeds from nasle of property, plant and equipment 5 (225.2) \$ (23.2) Proceeds from restricted investments - Asbestos (98.4) (60.5) (72.8) (80.0) Proceeds from restricted investments - Asbestos 94.6 (12.8) (80.0) Proceeds from restricted investments - Asbestos 94.6 (12.9) <td< td=""><td></td><td></td><td>16.6</td><td></td><td>18.9</td></td<> | | | 16.6 | | 18.9 |
| Inventories(31.3)42.9Operating lease assets and liabilities, net(17.0)(13.0)Prepaid expenses and other assets(17.4)(31.6)Insurance receivable - Asbestos2.12.3Accounts payable and accrued liabilities(11.7)53.8Claims and handling costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.7)Cash Flows From Investing Activities(12.8)(8.0)Purchases of property, plant and equipment-4.1Purchase of restricted investments - Asbestos(18.4)(80.5)Proceeds from restricted investments - Asbestos(18.4)(80.5)Proceeds from restricted investments - Asbestos(14.9)(121.3)Cash Flows From Inancing Activities\$(224.4)\$Proceeds from restricted investments - Asbestos(14.9)(121.3)Repayments of term loan(3.8)Proceeds from restricted investments - Asbestos(14.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility-(18.50)Proceeds from revolving credit facility-0.2Proceeds from revolving credit facility- | | | | | ((() |
| Operating lease assets and liabilities, net(17.0)(13.0)Prepaid expenses and other assets(17.4)(31.6)Insurance receivable - Asbestos2.12.3Accounts payable and accrued liabilities(11.7)53.8Claims and handling costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.4)Net cash provided by operating activities§ 364.3\$ 459.1Purchases of property, plant and equipment-4.1Capitalized interest(12.8)(60.5)Proceeds from restricted investments - Asbestos(98.4)(60.5)Purchases of property, plant and equipment-4.1Capitalized interest(12.8)(60.5)Proceeds from restricted investments - Asbestos94.647.7Other0.4Net cash used in investing activities\$ (241.4)\$ (241.4)Shares repurchased(149.9)(121.3)Repayments of term loan(3.8)-Proceeds from issuance of shares-0.2Repayment of inance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (155.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash an | | | | | , , |
| Prepaid expenses and other assets(17.4)(31.6)Insurance receivable - Asbestos2.12.3Accounts payable and accrued liabilities(11.7)53.8Claims and handling costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.4)Net cash provided by operating activities $$$ 364.3)\$Purchases of property, plant and equipment $$$ (225.2)\$(223.6)Proceeds from sale of property, plant and equipment $-$ -4.1Capitalized interest(12.8)(80.0)Purchase of restricted investments - Asbestos94.667.7Other0.4Net cash used in investing activities94.6(212.3)Shares repurchased(14.9)(121.3)Repayments of term loan(3.8)-Proceeds from issuance of shares-0.4Proceeds from issuance of shares-0.2Repayments of revolving credit facility-(145.0)Proceeds from issuance of shares-0.6Stares paid related to net share settlement of equily awards(2.2)Net cash used in financing activities\$(14.5)Stares paid related to ash and cash equivalents, restricted cash - Asbestos(30.0)Proceeds from issuance of shares-0.2Proceeds from source of shares-0.2Net cash used in financing activities\$(15.5)Stares paid relate | | | · · / | | |
| Insurance receivable - Asbestos2.12.3Accounts payable and accrued liabilities(11.7)53.8Claims and handling costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.4)Net cash provided by operating activities§364.3Cash Flows From Investing Activities(12.8)(8.0)Proceeds from sale of property, plant and equipment\$(225.2)\$Proceeds from sale of property, plant and equipment-4.1Capitalized interest(12.8)(8.0)Proceeds from restricted investments - Asbestos(98.4)(60.5)Proceeds from restricted investments - Asbestos94.647.7Other0.4Net cash used in investing activities\$(241.4)\$Shares repurchased(149.9)(121.3)Repayments of term loan(3.8)-Proceeds from issuance of shares-0.2Proceeds from issuance of shares-0.2Proceeds from issuance of shares-0.2States paid related to net share settlement of equivalents, restricted cash and restricted cash - Asbestos(30.0)Net cash used in financing activities\$(14.5)States repurchased(14.5)\$Cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)Repayments of term loan(6.5)\$States spid related to net share settlement of equily awards(2.2) <t< td=""><td></td><td></td><td>· · /</td><td></td><td></td></t<> | | | · · / | | |
| Accounts payable and accrued liabilities(11.7)53.8Claims and handing costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.4)Net cash provided by operating activities $$$ 364.3\$Purchases of property, plant and equipment $$$ (225.2)\$Proceeds from sale of property, plant and equipment $ -$ Proceeds from restricted investments - Asbestos(98.4)(60.5)Proceeds from restricted investments - Asbestos94.647.7Other 0.4 $-$ Net cash used in investing activities $$$ (241.4) $$$ (249.3)Cash Flows From Invacting Activities $$$ (241.4) $$$ (249.3)Cash Flows from restricted investments - Asbestos94.647.7Other 0.4 $-$ Net cash used in investing activities $$$ (241.4) $$$ (249.3)Cash Flows From Financing Activities $-$ 95.0Repayments of term loan $(14.9.9)$ (121.3) Proceeds from revolving credit facility $-$ 0.6Proceeds from revolving credit facility $-$ 0.62Repayments of term loan sisuance of shares $-$ 0.6Incase paid related to net share settlement of equity awards (2.2) (11.3) Net cash used in financing activities $$$ (156.5) $$$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash - Asbestos (30.0) $(6.2, 2)$ Cash and cash equivalents, rest | | | . , | | |
| Claims and handling costs paid - Asbestos(60.4)(60.3)Income taxes payable(11.7)(16.8)Other accrued liabilities(9.8)(11.4)Net cash provided by operating activities\$364.3\$Cash Flows From Investing Activities\$(225.2)\$(223.26)Proceeds from sale of property, plant and equipment\$(12.8)(80.0)Proceeds from sale of property, plant and equipment(12.8)(80.0)(80.4)(80.5)Proceeds from restricted investments - Asbestos94.647.7(12.8)(80.0)Purchase of restricted investments - Asbestos94.647.7-4.4-Net cash used in investing activities\$(241.4)\$(249.3)(212.3)Cash Flows From Financing Activities*4.5-Shares repurchased(149.9)(121.3)95.0Repayments of term loan(3.8)0.2Proceeds from revolving credit facility-0.2(145.0)-0.2Repayments of remoloning credit facility-0.2(12.2)(12.3)-0.2Repayments of term loan(0.6)(0.5)-0.2-0.2-0.2Repayments of remoloning credit facility-0.2-0.2-0.2-0.2-0.2-0.2-0.20.20.20.2 | | | | | |
| Income taxes payable (11.7) (16.8) Other accrued liabilities (9.8) (11.4) Net cash provided by operating activities 343.3 \$ 459.1 Cash Flows From Investing Activities 9 362.3 \$ (225.2) \$ (| | | | | |
| Other accrued liabilities (9.8) (11.4) Net cash provided by operating activities \$ 364.3 \$ 459.1 Cash Flows From Investing Activities - - Purchases of property, plant and equipment - - Capitalized interest (12.8) (232.6) Proceeds from sale of property, plant and equipment - - Capitalized interest (12.8) (80.0) Purchase of restricted investments - Asbestos (98.4) (60.5) Proceeds from restricted investments - Asbestos (98.4) (60.5) Proceeds from restricted investments - Asbestos (98.4) (241.3) Cash Flows From Financing Activities \$ (241.4) \$ (249.3) Cash Flows From Financing Activities \$ (241.3) \$ - Shares repurchased (149.9) (121.3) - - 95.0 Repayments of tern loan - Proceeds from issuance of shares - | | | . , | | |
| Net cash provided by operating activities \$ 364.3 \$ 459.1 Cash Flows From Investing Activities | | | | | |
| Cash Flows From Investing Activities - - 4.1 Purchases of property, plant and equipment - - 4.1 Capitalized interest (12.8) (8.0) Purchase of restricted investments - Asbestos (98.4) (60.5) Proceeds from restricted investments - Asbestos 94.6 47.7 Other 0.4 - Net cash used in investing activities \$ (241.4) \$ (241.4) Shares repurchased (149.9) (121.3) Repayments of term loan (3.8) - Proceeds from issuance of shares - 0.4 Proceeds from issuance of shares - 0.2 Repayments of revolving credit facility - 0.2 Repayments of revolving credit facility - 0.2 Repayments of finance lease obligations (0.6) (0.5) Taxes paid related to net share settlement of equity awards (2.2) (1.3) Net cash used in financing activities \$ (156.5) \$ (212.9) Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos (30.0) (6.2) Cash and cash equivalents, restricted | | - | . , | _ | |
| Purchases of property, plant and equipment \$ (225.2) \$ (226.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) \$ (227.2) < | | \$ | 364.3 | \$ | 459.1 |
| Proceeds from sale of property, plant and equipment | | • | (005.0) | • | (000.0) |
| Capitalized interest(12.8)(8.0)Purchase of restricted investments - Asbestos(98.4)(60.5)Proceeds from restricted investments - Asbestos94.647.7Other0.4Net cash used in investing activities\$ (241.4)\$ (249.3)Cash Flows From Financing Activities(149.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility95.0Repayments of revolving credit facility(185.0)Proceeds from revolving credit facility0.2Repayments of revolving credit facility0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net shares settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (241.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash - Asbestos at beginning of period\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 30.2\$ 22.5 | | \$ | (225.2) | \$ | |
| Purchase of restricted investments - Asbestos(98.4)(60.5)Proceeds from restricted investments - Asbestos94.647.7Other0.4Net cash used in investing activities\$ (241.4)\$ (249.3)Cash Flows From Financing Activities(149.9)(121.3)Shares repurchased(149.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility(185.0)Proceeds from revolving credit facility(185.0)Proceeds from issuance of shares0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$ 385.8\$ 179.4Non-Cash Investing and Financing Activities\$ 30.2\$ 22.5\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 30.2\$ 22.5 | | | - | | |
| Proceeds from restricted investments - Asbestos94.647.7Other0.4Net cash used in investing activities\$ (241.4)\$ (249.3)Cash Flows From Financing Activities(149.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility95.0Repayments of term loan(185.0)Proceeds from issuance of shares0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos3.6\$ (3.1)Net decrease in cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash - Asbestos at beginning of period\$ 3.0.2\$ 22.5Non-Cash Investing and Financing Activities\$ 3.0.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 3.0.2\$ 22.5 | | | | | , |
| Other0.4-Net cash used in investing activities\$ (241.4)\$ (249.3)Cash Flows From Financing Activities(149.9)(121.3)Shares repurchased(149.9)(121.3)Repayments of term Ioan(3.8)-Proceeds from revolving credit facility-95.0Repayments of revolving credit facility-(185.0)Proceeds from issuance of shares-0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$ 385.8179.4Non-Cash Investing and Financing Activities\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 30.2\$ 22.5 | | | , , | | |
| Net cash used in investing activities\$ (241.4)\$ (249.3)Cash Flows From Financing Activities(149.9)(121.3)Shares repurchased(149.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility95.0Repayments of revolving credit facility(185.0)Proceeds from issuance of shares0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Net decrease in cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash - Asbestos at end of period\$ 385.8\$ 179.4Non-Cash Investing and Financing Activities\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 30.2\$ 22.5 | | | | | 47.7 |
| Cash Flows From Financing ActivitiesShares repurchased(149.9)(121.3)Repayments of term loan(3.8)Proceeds from revolving credit facility(95.0)Repayments of revolving credit facility(185.0)Proceeds from issuance of shares0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$(156.5)\$Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Net decrease in cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$385.8\$Non-Cash Investing and Financing Activities\$30.2\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.5 | | <u>^</u> | | | (0.40, 0) |
| Shares repurchased(149.9)(121.3)Repayments of term loan(3.8)—Proceeds from revolving credit facility—95.0Repayments of revolving credit facility—(185.0)Proceeds from issuance of shares—0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$(156.5)\$Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$385.8\$Non-Cash Investing and Financing Activities\$30.2\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.5 | | \$ | (241.4) | \$ | (249.3) |
| Repayments of term loan(3.8)—Proceeds from revolving credit facility—95.0Repayments of revolving credit facility—(185.0)Proceeds from issuance of shares—0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$(156.5)\$Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Net decrease in cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$385.8\$Non-Cash Investing and Financing Activities\$30.2\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.5 | | | (4.40.0) | | (101.0) |
| Proceeds from revolving credit facility–95.0Repayments of revolving credit facility–(185.0)Proceeds from issuance of shares–0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$(156.5)\$Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos\$3.6\$Net decrease in cash and cash equivalents, restricted cash - Asbestos(30.0)(6.2)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$385.8\$179.4Non-Cash Investing and Financing Activities\$30.2\$22.5\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.5\$ | | | . , | | (121.3) |
| Repayments of revolving credit facility–(185.0)Proceeds from issuance of shares–0.2Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$(156.5)\$Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos\$3.6\$Net decrease in cash and cash equivalents, restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$30.2\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.522.5 | · · · | | (3.8) | | - |
| Proceeds from issuance of shares - 0.2 Repayment of finance lease obligations (0.6) (0.5) Taxes paid related to net share settlement of equity awards (2.2) (1.3) Net cash used in financing activities \$ (156.5) \$ (212.9) Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos \$ 3.6 \$ (3.1) Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos (30.0) (6.2) Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period 415.8 185.6 Non-Cash Investing and Financing Activities \$ 30.2 \$ 22.5 Supplemental Disclosure of Cash Flow Activities \$ 30.2 \$ 22.5 | | | _ | | |
| Repayment of finance lease obligations(0.6)(0.5)Taxes paid related to net share settlement of equity awards(2.2)(1.3)Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos\$ 3.6\$ (3.1)Net decrease in cash and cash equivalents, restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$ 385.8\$ 179.4Non-Cash Investing and Financing Activities\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 30.2\$ 22.5 | | | — | | . , |
| Taxes paid related to net share settlement of equity awards (2.2) (1.3) Net cash used in financing activities \$ (156.5) \$ (212.9) Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos \$ 3.6 \$ (3.1) Net decrease in cash and cash equivalents, restricted cash - Asbestos (30.0) (6.2) Cash and cash equivalents, restricted cash - Asbestos at beginning of period 415.8 185.6 Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period \$ 30.2 \$ 22.5 Non-Cash Investing and Financing Activities \$ 30.2 \$ 22.5 Supplemental Disclosure of Cash Flow Activities \$ 30.2 \$ 22.5 | | | (0, 0) | | |
| Net cash used in financing activities\$ (156.5)\$ (212.9)Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos\$ 3.6\$ (3.1)Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8179.4Non-Cash Investing and Financing Activities\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities\$ 22.5 | | | | | |
| Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos \$ 3.6 \$ (3.1) Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos (30.0) (6.2) Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period 415.8 185.6 185.6 Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period 415.8 185.6 179.4 Non-Cash Investing and Financing Activities \$ 30.2 \$ 22.5 \$ 22.5 Supplemental Disclosure of Cash Flow Activities \$ 30.2 \$ 22.5 \$ 30.2 \$ 22.5 | | ^ | | <u>^</u> | |
| Asbestos\$3.6\$(3.1)Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos(30.0)(6.2)Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period415.8185.6Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period\$385.8\$Non-Cash Investing and Financing Activities\$30.2\$22.5Supplemental Disclosure of Cash Flow Activities\$30.2\$22.5 | | \$ | (156.5) | \$ | (212.9) |
| Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period 415.8 185.6 Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period \$ 385.8 \$ 179.4 Non-Cash Investing and Financing Activities \$ 30.2 \$ 22.5 Supplemental Disclosure of Cash Flow Activities \$ 30.2 \$ 22.5 | Asbestos | \$ | 3.6 | \$ | (3.1) |
| Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period \$ 385.8 \$ 179.4 Non-Cash Investing and Financing Activities \$ 30.2 \$ 22.5 Capital expenditures incurred but not yet paid \$ 30.2 \$ 22.5 Supplemental Disclosure of Cash Flow Activities \$ 22.5 | Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos | | (30.0) | | (6.2) |
| period\$ 385.8\$ 179.4Non-Cash Investing and Financing Activities | Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period | | 415.8 | | 185.6 |
| Capital expenditures incurred but not yet paid\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities | | \$ | 385.8 | \$ | 179.4 |
| Capital expenditures incurred but not yet paid\$ 30.2\$ 22.5Supplemental Disclosure of Cash Flow Activities | Non-Cash Investing and Financing Activities | | | | |
| Supplemental Disclosure of Cash Flow Activities | | \$ | 30.2 | \$ | 22.5 |
| Cash paid to AICF \$ 24.8 \$ 23.0 | | | | | |
| | Cash paid to AICF | \$ | 24.8 | \$ | 23.0 |

James Hardie Industries plc Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)

| | | | | Th | Three Months Ended 30 September 2024 | | | | | | | | | | |
|----------------------------------|----|---|----|-------|--------------------------------------|-------------------------------------|----|------------|---|--------|----|---------|--|--|--|
| (Millions of US dollars) | (| Additional Common Paid-in Stock Capital | | | | Retained Treasury Earnings Stock | | | Accumulated Other Comprehensive Loss | | | Total | | | |
| Balances as of 30 June 2024 | \$ | 223.2 | \$ | 259.4 | \$ | 1,529.2 | \$ | <u> </u> | \$ | (74.8) | \$ | 1,937.0 | | | |
| Net income | | _ | | _ | | 83.4 | | _ | | _ | | 83.4 | | | |
| Other comprehensive income | | _ | | _ | | _ | | _ | | 25.2 | | 25.2 | | | |
| Stock-based compensation | | 0.1 | | 5.9 | | _ | | _ | | _ | | 6.0 | | | |
| Issuance of ordinary shares | | _ | | 0.1 | | _ | | _ | | _ | | 0.1 | | | |
| Shares repurchased | | _ | | _ | | _ | | (74.9) | | _ | | (74.9) | | | |
| Shares cancelled | | (1.4) | | (1.3) | _ | (72.2) | | 74.9 | | _ | | _ | | | |
| Balances as of 30 September 2024 | \$ | 221.9 | \$ | 264.1 | \$ | 1,540.4 | \$ |) — | \$ | (49.6) | \$ | 1,976.8 | | | |

| | | | | S | ix I | Months Ended | 30 | September 202 | 24 | | | |
|----------------------------------|---|-------|----|-------|-------------------------------------|--------------|----|---|----|--------|-------|---------|
| (Millions of US dollars) | Additional Common Paid-in Stock Capital | | | | Retained Treasury Earnings Stock | | | Accumulated Other Comprehensive Loss | | | Total | |
| Balances as of 31 March 2024 | \$ | 224.7 | \$ | 256.5 | \$ | 1,446.0 | \$ | ; _ | \$ | (68.3) | \$ | 1,858.9 |
| Net income | | _ | | _ | | 238.7 | | _ | | _ | | 238.7 |
| Other comprehensive income | | _ | | _ | | _ | | _ | | 18.7 | | 18.7 |
| Stock-based compensation | | 0.1 | | 10.0 | | _ | | _ | | — | | 10.1 |
| Issuance of ordinary shares | | _ | | 0.3 | | | | | | _ | | 0.3 |
| Shares repurchased | | _ | | — | | _ | | (149.9) | | _ | | (149.9) |
| Shares cancelled | | (2.9) | | (2.7) | | (144.3) | | 149.9 | | | | |
| Balances as of 30 September 2024 | \$ | 221.9 | \$ | 264.1 | \$ | 1,540.4 | \$ | ; | \$ | (49.6) | \$ | 1,976.8 |

| | | | | Th | ree | Months Endeo | d 30 | September 20 |)23 | | | |
|----------------------------------|---|-------|----|-------|-------------------------------------|--------------|------|---|-----|--------|-------|---------|
| (Millions of US dollars) | Additional Common Paid-in Stock Capital | | | | Retained Treasury Earnings Stock | | | Accumulated Other Comprehensive Loss | | | Total | |
| Balances as of 30 June 2023 | \$ | 228.7 | \$ | 243.0 | \$ | 1,308.0 | \$ | | \$ | (60.3) | \$ | 1,719.4 |
| Net income | | _ | | _ | | 151.7 | | _ | | _ | | 151.7 |
| Other comprehensive loss | | _ | | _ | | _ | | _ | | (15.8) | | (15.8) |
| Stock-based compensation | | 0.1 | | 4.8 | | _ | | _ | | _ | | 4.9 |
| Issuance of ordinary shares | | _ | | 0.1 | | _ | | _ | | _ | | 0.1 |
| Shares repurchased | | _ | | _ | | _ | | (72.3) | | _ | | (72.3) |
| Shares cancelled | | (1.5) | | (1.4) | | (69.4) | | 72.3 | | _ | | _ |
| Balances as of 30 September 2023 | \$ | 227.3 | \$ | 246.5 | \$ | 1,390.3 | \$ | _ | \$ | (76.1) | \$ | 1,788.0 |

James Hardie Industries plc Condensed Consolidated Statements of Changes in Shareholders' Equity (continued) (Unaudited)

| | | | | S | ix | Months Ended | 30 | September 202 | 23 | | | |
|----------------------------------|---|-------|----|-------|-------------------------------------|--------------|----|---|----|--------|-------|---------|
| (Millions of US dollars) | Additional Common Paid-in Stock Capital | | | | Retained Treasury Earnings Stock | | | Accumulated Other Comprehensive Loss | | | Total | |
| Balances as of 31 March 2023 | \$ | 230.0 | \$ | 237.9 | \$ | 1,196.8 | \$ | ; | \$ | (53.3) | \$ | 1,611.4 |
| Net income | | — | | _ | | 309.5 | | _ | | _ | | 309.5 |
| Other comprehensive loss | | _ | | _ | | _ | | — | | (22.8) | | (22.8) |
| Stock-based compensation | | 0.1 | | 10.9 | | _ | | _ | | — | | 11.0 |
| Issuance of ordinary shares | | _ | | 0.2 | | _ | | — | | _ | | 0.2 |
| Shares repurchased | | — | | _ | | _ | | (121.3) | | — | | (121.3) |
| Shares cancelled | | (2.8) | | (2.5) | | (116.0) | _ | 121.3 | | _ | | _ |
| Balances as of 30 September 2023 | \$ | 227.3 | \$ | 246.5 | \$ | 1,390.3 | \$ | <u> </u> | \$ | (76.1) | \$ | 1,788.0 |

1. Organization and Significant Accounting Policies

Nature of Operations

James Hardie Industries plc ("JHI plc") manufactures and sells fiber cement, fiber gypsum and cementbonded building products for interior and exterior building construction applications, primarily in the United States, Australia, Europe, New Zealand and the Philippines. In August 2024, the Company ceased manufacturing and began winding down commercial operations in the Philippines.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto, included in the Company's Annual Report on Form 20-F for the fiscal year ended 31 March 2024 from which the prior year balance sheet information herein was derived. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosures. Actual results could differ from those estimates.

The condensed consolidated financial statements represent the financial position, results of operations and cash flows of JHI plc and its wholly-owned subsidiaries and variable interest entity ("VIE"). Unless the context indicates otherwise, JHI plc and its direct and indirect wholly-owned subsidiaries and VIE (as of the time relevant to the applicable reference) are collectively referred to as "James Hardie", the "James Hardie Group" or the "Company". All intercompany balances and transactions have been eliminated in consolidation. In management's opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation of the results for the interim periods presented.

The Company has recorded on its condensed consolidated balance sheets certain foreign assets and liabilities, that are denominated in foreign currencies and subject to translation or remeasurement into US dollars at each reporting date under the applicable accounting guidance. Unless otherwise noted, the Company converts foreign currency denominated assets and liabilities into US dollars at the spot rate at the end of the reporting period; while revenues and expenses are converted using an average exchange rate for the period.

The gains and losses on the remeasurement of the Company's Euro denominated debt are economically offset by foreign exchange gains and losses on loans between subsidiaries, resulting in a net immaterial translation gain or loss which is recorded in the *Selling, general and administrative expenses* in the condensed consolidated statements of operations and comprehensive income.

Summary of Significant Accounting Policies

During the six months ended 30 September 2024, there were no changes to our significant accounting policies as described in our Annual Report on Form 20-F for the fiscal year ended 31 March 2024.

Accounting Standards Issued But Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting (Topic 280). The amendments in the standard were issued to improve the disclosures about an entity's reportable segments and address requests from investors for additional, more detailed information about a reportable segment's expenses. These amendments are effective for fiscal years beginning after 15 December 2023, and interim periods within fiscal years beginning after 15 December 2024, with early adoption permitted. The Company will adopt ASU No. 2023-07 starting with its Form 20-F for the fiscal year ending 31 March 2025 and will be required to make additional disclosures in the notes to the consolidated financial statements.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The amendments in this standard enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. These amendments are effective for fiscal years beginning after 15 December 2024, with early adoption permitted. The Company will adopt ASU No. 2023-09 starting with its Form 20-F for the fiscal year ending 31 March 2026 and will be required to make additional disclosures in the notes to the consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). The amendments in this standard were issued to improve interim and annual reporting disclosures by breaking down expenses into specific categories in a clear, tabular format. These amendments are effective for fiscal years beginning after 15 December 2026, and interim periods within fiscal years beginning after 15 December 2027, with early adoption permitted. The Company plans to adopt ASU No. 2024-03 starting with its Form 20-F for the fiscal year ending 31 March 2028 and will be required to make additional disclosures in the notes to the consolidated financial statements.

Earnings Per Share

Basic earnings per share ("EPS") is calculated using net income divided by the weighted average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares calculated using the treasury method that would have been outstanding if the dilutive potential common shares, such as stock options and restricted stock units, had been issued.

Basic and diluted common shares outstanding used in determining net income per share are as follows:

| | | Months September | Six Months Ended 30 September | | | | |
|-----------------------------------|-------|---------------------|----------------------------------|-------|--|--|--|
| (Millions of shares) | 2024 | 2023 | 2024 | 2023 | | | |
| Basic common shares outstanding | 430.8 | 439.6 | 432.0 | 440.7 | | | |
| Dilutive effect of stock awards | 1.5 | 1.2 | 1.4 | 1.1 | | | |
| Diluted common shares outstanding | 432.3 | 440.8 | 433.4 | 441.8 | | | |

There were no potential common shares which would be considered anti-dilutive for the three and six months ended 30 September 2024 and 2023.

Potential common shares of 0.6 million for both the three and six months ended 30 September 2024, and 0.6 million and 0.5 million for the three and six months ended 30 September 2023, respectively, have been excluded from the calculation of diluted common shares outstanding as they are considered contingent shares which are not expected to vest.

2. Revenues

The following represents the Company's disaggregated revenues:

| | Thr | ee M | onths Ende | d 30 | September 2 | 024 | |
|--------------------------|---------------------------|------|-------------------------|------|---------------------------|-----|------------|
| (Millions of US dollars) | n America r Cement | | ia Pacific er Cement | | rope Building Products | Co | nsolidated |
| Fiber cement revenues | \$ 695.8 | \$ | 148.4 | \$ | 22.3 | \$ | 866.5 |
| Fiber gypsum revenues | — | | _ | | 94.3 | | 94.3 |
| Total revenues | \$ 695.8 | \$ | 148.4 | \$ | 116.6 | \$ | 960.8 |

Three Months Ended 30 September 2023

| (Millions of US dollars) | America Cement | a Pacific er Cement | rope Building Products | Co | nsolidated |
|--------------------------|-----------------------|------------------------|---------------------------|----|------------|
| Fiber cement revenues | \$ 734.4 | \$ 147.4 | \$ 20.5 | \$ | 902.3 |
| Fiber gypsum revenues | — | — | 96.5 | | 96.5 |
| Total revenues | \$ 734.4 | \$ 147.4 | \$ 117.0 | \$ | 998.8 |

| | | Six Months Ended 30 September 2024 | | | | | | | | | | | |
|--------------------------|-----------------------|------------------------------------|--------------------------|-----------------------------|-----|-----------|--|--|--|--|--|--|--|
| (Millions of US dollars) | North Am Fiber Cer | | sia Pacific er Cement | Europe Building Products | Con | solidated | | | | | | | |
| Fiber cement revenues | \$ 1,4 | 25.1 \$ | 283.7 | \$ 43.5 | \$ | 1,752.3 | | | | | | | |
| Fiber gypsum revenues | | | | 200.4 | | 200.4 | | | | | | | |
| Total revenues | \$ 1,4 | 25.1 \$ | 283.7 | \$ 243.9 | \$ | 1,952.7 | | | | | | | |

Six Months Ended 30 September 2023

| (Millions of US dollars) | h America r Cement | ia Pacific er Cement | Ει | rope Building Products | Consolidated | | |
|--------------------------|-----------------------|-------------------------|----|---------------------------|--------------|---------|--|
| Fiber cement revenues | \$ 1,429.2 | \$ 287.5 | \$ | 41.5 | \$ | 1,758.2 | |
| Fiber gypsum revenues | _ | _ | | 194.9 | | 194.9 | |
| Total revenues | \$ 1,429.2 | \$ 287.5 | \$ | 236.4 | \$ | 1,953.1 | |

The process by which the Company recognizes revenues is similar across each of the Company's reportable segments. Fiber cement and fiber gypsum revenues are primarily generated from the sale of siding and various boards used in external and internal applications, as well as accessories. Fiber gypsum revenues also includes the sale of cement-bonded boards in the Europe Building Products segment.

3. Cash and Cash Equivalents, Restricted Cash and Restricted Cash - Asbestos

The following table provides a reconciliation of *Cash and cash equivalents, Restricted cash and Restricted cash - Asbestos* reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

| | 30 S | eptember | | 31 March | |
|----------------------------|------|----------|------|----------|--|
| (Millions of US dollars) | | 2024 | 2024 | | |
| Cash and cash equivalents | \$ | 368.1 | \$ | 365.0 | |
| Restricted cash | | 5.0 | | 5.0 | |
| Restricted cash - Asbestos | | 12.7 | | 45.8 | |
| Total | \$ | 385.8 | \$ | 415.8 | |

Restricted cash relates to an insurance policy which restricts the cash from general corporate purposes.

Restricted cash - Asbestos is restricted to the settlement of asbestos claims and for the payment of the operating costs of Asbestos Injuries Compensation Fund ("AICF").

4. Inventories

Inventories consist of the following components:

| | 30 S | eptember | 31 March |
|---|------|----------|-------------|
| (Millions of US dollars) | | 2024 | 2024 |
| Finished goods | \$ | 266.6 | \$ 235.4 |
| Work-in-process | | 27.1 | 25.1 |
| Raw materials and supplies | | 90.3 | 90.6 |
| Provision for obsolete finished goods and raw materials | | (11.3) | (13.3) |
| Total | \$ | 372.7 | \$ 337.8 |

5. Restructuring Expenses

Restructuring expenses consists of the following:

| | Restructuring Expenses | | | | | | | |
|--|------------------------------------|------|----|------|----------------------|------|----|------|
| | Three Months Ended 30 September | | | | Six Mo Ended 30 S | | | |
| (Millions of US dollars) | 2 | 2024 | | 2023 | | 2024 | | 2023 |
| Equipment write offs, including disposal costs | \$ | 31.1 | \$ | | \$ | 31.1 | \$ | |
| Reclassification of foreign currency translation adjustments | | 8.3 | | | | 8.3 | | _ |
| Contract termination costs | | 4.6 | | | | 4.6 | | — |
| Accounts receivable reserves | | 3.4 | | | | 3.4 | | _ |
| Other exit costs | | 9.9 | | | | 9.9 | | |
| Asia Pacific Fiber Cement segment | | 57.3 | | _ | | 57.3 | | |
| General Corporate | | _ | | 20.1 | | _ | | 20.1 |
| Total | \$ | 57.3 | \$ | 20.1 | \$ | 57.3 | \$ | 20.1 |

Asia Pacific Fiber Cement segment

For the quarter ending 30 September 2024, the Company recorded US\$57.3 million of exit costs related to its decision to shut down its manufacturing and wind-down commercial operations in the Philippines. The net assets remaining in the Philippines primarily consists of land and buildings, which the Company is preparing to sell.

General Corporate

For the quarter ending 30 September 2023, the Company recorded impairment charges based on the strategic decision to cancel the Truganina greenfield site. The site is classified as held for-sale and the estimated fair value of US\$52.6 million at that time was derived primarily from market comparables using a third-party appraisal and are considered Level 3 inputs under ASC 820.

6. Debt

The Company's debt obligations are as follows:

| | 30 September | | 31 March |
|--|--------------|-----------|---------------|
| (Millions of US dollars) | | 2024 | 2024 |
| Unsecured debt: | | | |
| 3.625% Senior notes due 2026 (€400.0 million) | \$ | 446.5 | \$ 431.0 |
| 5.000% Senior notes due 2028 | | 400.0 | 400.0 |
| Term Loan | | 294.4 | 298.1 |
| Unamortized debt issuance costs | | (5.6) | (6.5) |
| Total debt | | 1,135.3 | 1,122.6 |
| Less current portion | | (7.5) | (7.5) |
| Total Long-term debt | \$ | 1,127.8 | \$ 1,115.1 |
| | | | |
| Weighted average interest rate of total debt | | 5.1 % | 5.1 % |
| Weighted average term of available total debt | | 2.7 years | 3.2 years |
| | | | |
| Fair value of Senior unsecured notes (Level 1) | \$ | 820.2 | \$ 811.5 |

As of 30 September 2024, the Company had a total borrowing base capacity under its unsecured revolving credit facility of US\$600.0 million with outstanding borrowings of nil, and US\$6.1 million of issued but undrawn letters of credit and bank guarantees. These letters of credit and bank guarantees relate to various operational matters including insurance, performance bonds and other items, leaving the Company with US\$593.9 million of available borrowing capacity under the revolving credit facility.

As of 30 September 2024, the Company was in compliance with all of its covenants contained in the senior unsecured notes, term loan and the unsecured revolving credit facility agreement.

7. Asbestos

The following is a detailed rollforward of the Net Unfunded Amended and Restated Final Funding Agreement ("AFFA") liability, net of tax, for the six months ended 30 September 2024.

| (Millions of US dollars) | Asbestos Liability | Insurance Receivables | Restricted Cash and Investments | Other Assets and Liabilities | Net Unfunded AFFA Liability | Deferred Tax Assets | Income Tax Payable | Net Unfunded AFFA Liability, net of tax |
|---|-----------------------|--------------------------|---------------------------------------|---------------------------------------|--------------------------------------|---------------------------|--------------------------|---|
| Opening Balance - 31 March 2024 | \$ (989.7) | \$ 31.5 | \$ 224.2 | \$ 1.5 | \$ (732.5) | \$ 294.0 | \$ 39.5 | \$ (399.0) |
| Asbestos claims paid | 59.8 | _ | (59.8) | _ | _ | _ | _ | _ |
| Payment received in accordance with AFFA | _ | _ | 24.8 | _ | 24.8 | _ | _ | 24.8 |
| AICF claims-handling costs incurred (paid) | 0.6 | _ | (0.6) | _ | _ | _ | _ | _ |
| AICF operating costs paid - non claims-handling | _ | _ | (1.5) | _ | (1.5) | _ | _ | (1.5) |
| Insurance recoveries | _ | (2.1) | 2.1 | _ | _ | _ | _ | _ |
| Movement in income taxes | _ | _ | _ | _ | _ | (19.9) | (20.1) | (40.0) |
| Other movements | _ | _ | 4.2 | 1.4 | 5.6 | (1.2) | (0.1) | 4.3 |
| Effect of foreign exchange | (61.7) | 1.9 | 13.4 | 0.1 | (46.3) | 18.3 | 1.2 | (26.8) |
| Closing Balance - 30 September 2024 | \$ (991.0) | \$ 31.3 | \$ 206.8 | \$ 3.0 | \$ (749.9) | \$ 291.2 | \$ 20.5 | \$ (438.2) |

Claims Data

The following table shows the activity related to the numbers of open claims, new claims and closed claims during each of the past five years and the average settlement per settled claim and case closed:

| | Six Months Ended | | | | | | | | | | |
|--|---------------------|-------------|-------------|-------------|-------------|-------------|--|--|--|--|--|
| | 30 September 2024 | 2024 | 2023 | 2022 | 2021 | 2020 | | | | | |
| Number of open claims at beginning of period | 379 | 359 | 365 | 360 | 393 | 332 | | | | | |
| Number of new claims | | | | | | | | | | | |
| Direct claims | 220 | 410 | 403 | 411 | 392 | 449 | | | | | |
| Cross claims | 126 | 154 | 152 | 144 | 153 | 208 | | | | | |
| Number of closed claims | 298 | 544 | 561 | 550 | 578 | 596 | | | | | |
| Number of open claims at end of period | 427 | 379 | 359 | 365 | 360 | 393 | | | | | |
| Average settlement amount per settled claim | A\$335,000 | A\$289,000 | A\$303,000 | A\$314,000 | A\$248,000 | A\$277,000 | | | | | |
| Average settlement amount per case closed ¹ | A\$299,000 | A\$262,000 | A\$271,000 | A\$282,000 | A\$225,000 | A\$245,000 | | | | | |
| | | | | | | | | | | | |
| Average settlement amount per settled claim | US\$223,000 | US\$190,000 | US\$208,000 | US\$232,000 | US\$178,000 | US\$189,000 | | | | | |
| Average settlement amount per case closed ¹ | US\$199,000 | US\$172,000 | US\$186,000 | US\$208,000 | US\$162,000 | US\$167,000 | | | | | |

¹ The average settlement amount per case closed includes nil settlements.

Under the terms of the AFFA, the Company has rights of access to actuarial information produced for AICF by the actuary appointed by AICF, which is currently KPMG. The Company's disclosures with respect to claims statistics are subject to it obtaining such information, however, the AFFA does not provide the Company an express right to audit or otherwise require independent verification of such information or the methodologies to be adopted by the approved actuary. As such, the Company relies on the accuracy and completeness of the information provided by AICF to the approved actuary and the resulting information and analysis of the approved actuary when making disclosures with respect to claims statistics.

AICF Funding

During fiscal year 2025, the Company will contribute A\$149.6 million to AICF, excluding interest, in quarterly installments. The first two payments of A\$37.4 million were made on 1 July 2024 and 1 October 2024.

For the six months ended 30 September 2024, the Company did not provide financial or other support to AICF that it was not previously contractually required to provide.

Restricted Investments

AICF invests its excess cash in time deposits, which are classified as held to maturity investments and the carrying value materially approximates the fair value for each investment. The following table represents the investments outstanding as of 30 September 2024:

| Date Invested | Maturity Date | Interest Rate | A\$ Millions |
|---------------|-----------------|---------------|--------------|
| July 2024 | 24 July 2025 | 5.25% | 60.0 |
| April 2024 | 14 April 2025 | 5.12% | 36.0 |
| April 2024 | 7 April 2025 | 5.08% | 54.0 |
| January 2024 | 24 January 2025 | 5.20% | 60.0 |
| October 2023 | 16 October 2024 | 5.13% | 70.0 |

8. Commitments and Contingencies

Legal Matters

The Company is involved from time to time in various legal proceedings and administrative actions related to the normal conduct of its business, including general liability claims, putative class action lawsuits and litigation concerning its products.

Although it is impossible to predict the outcome of any pending legal proceeding, management believes that such proceedings and actions should not, individually or in the aggregate, have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows, except as described in these condensed consolidated financial statements.

New Zealand Weathertightness Claims

Since fiscal year 2002, the Company's New Zealand subsidiaries have been joined in a number of weathertightness claims in New Zealand that relate to residential buildings (single dwellings and apartment complexes) and a small number of non-residential buildings, primarily constructed from 1998 to 2004. The claims often involve multiple parties and allege that losses were incurred due to excessive moisture penetration of the buildings' structures. The claims typically include allegations of poor building

design, inadequate certification of plans, inadequate construction review and compliance certification and deficient work by sub-contractors.

Historically, the Company's New Zealand subsidiaries have been joined to these claims as one of several co-defendants, including local government entities responsible for enforcing building codes and practices, resulting in the Company's New Zealand subsidiaries becoming liable for only a portion of each claim. In addition, the Company's New Zealand subsidiaries have had access to third-party recoveries to defray a portion of the costs incurred in resolving such claims.

There remains only one material outstanding New Zealand Weathertightness Claim, Cridge, et al. (*Case Nos. CIV-2015-485-594 and CIV-2015-485-773*), *In the High Court of New Zealand, Wellington Registry* (hereinafter the "Cridge litigation"), which was filed in 2015 on behalf of multiple plaintiffs against the Company and/or its subsidiaries as the sole defendants, which alleges that the New Zealand subsidiaries' products were inherently defective. The Company believes it has substantial factual and legal defenses to the claim and is defending the claim vigorously.

From August to December 2020, the trial of phase one of the Cridge litigation was held in Wellington, New Zealand solely to determine whether the Company's New Zealand subsidiaries had a duty to the plaintiffs and breached that duty. In August 2021, the Wellington High Court issued its decision finding in favor of the Company on all claims (the "Cridge Decision"). In September 2021, plaintiffs filed a notice of appeal of the trial court's decision, and subsequently the appellate court held a hearing in August 2022. In September 2024, the appellate court issued its decision, dismissing the plaintiffs' appeal in its entirety. In October 2024, plaintiffs filed for leave to appeal with the New Zealand Supreme Court. As of 30 September 2024, the Company has not recorded a reserve related to the Cridge litigation as the chance of loss remains not probable following the Cridge Decision and dismissal of the appeal. An adverse judgement on the Cridge matter could have a material adverse impact on our consolidated financial position, results of operations or cash flows.

Australia Class Action Securities Claim

On 8 May 2023, a group proceeding (class action) was filed in The Supreme Court of Victoria, Australia by Raeken Pty Ltd against James Hardie Industries plc on behalf of persons who purchased certain James Hardie equity securities from 7 February 2022, through 7 November 2022. The litigation is being funded by a litigation funder in Australia, CASL Funder Pty Ltd. The proceeding includes allegations that James Hardie breached relevant provisions of the Corporations Act 2001 (Cth) and the Australian and Securities Investment Act 2001 (Cth), including with respect to certain forward-looking statements James Hardie made about forecasted financial performance measures during the period specified above. The Company believes the challenged statements were proper and will defend the allegations vigorously. As of 30 September 2024, the Company has not recorded a reserve related to this matter as the chance of loss is not probable and the amount of loss, if any, cannot be reasonably estimated.

Australian Tax Office ("ATO") Audit

In February 2024, the ATO issued a transfer pricing position paper for income years starting 1 April 2010 through 31 March 2019, setting out the ATO's view that certain profits related to arrangements with the Company's technology holding company based in Ireland should be allocated to Australian subsidiaries of the Company and taxed in Australia. The Company believes its transfer pricing arrangements are compliant with the applicable tax legislation. As of 30 September 2024, the matter is ongoing and the Company has not recorded a reserve as it believes its tax position is more likely than not to be sustained. If the Company is ultimately unsuccessful in disputing the ATO's position, the ATO has calculated the additional amount of tax payable to be approximately A\$110 million, excluding any consequential adjustments, interest charges or penalties the ATO may impose.

Environmental

The operations of the Company, like those of other companies engaged in similar businesses, are subject to a number of laws and regulations on air, soil and water quality, waste handling and disposal. The Company's policy is to accrue for environmental costs when it is determined that it is probable that an obligation exists and the amount can be reasonably estimated.

9. Income Taxes

Income taxes payable represents taxes currently payable which are computed at statutory income tax rates applicable to taxable income derived in each jurisdiction in which the Company conducts business. During the six months ended 30 September 2024, the Company paid taxes, net of refunds, of US\$81.1 million.

Income tax expense differs from the statutory rate primarily due to the Company's mix of pre-tax income by jurisdiction and foreign taxes on domestic income.

Deferred income taxes include net operating loss carry-forwards. At 30 September 2024, the Company had tax loss carry-forwards in Australia, New Zealand, Europe and the US of approximately US\$82.4 million that are available to offset future taxable income in the respective jurisdiction. The Company establishes a valuation allowance against a deferred tax asset if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

The Australian tax loss carry-forwards primarily result from current and prior year tax deductions for contributions to AICF. James Hardie 117 Pty Limited, the performing subsidiary under the AFFA, is able to claim a tax deduction for its contributions to AICF over a five-year period commencing in the year the contribution is incurred. At 30 September 2024, the Company recognized a tax deduction of US\$66.1 million (A\$99.5 million) for the current year relating to total contributions to AICF of US\$702.4 million (A\$994.7 million) incurred in tax years 2021 through 2025.

10. Stock-Based Compensation

Total stock-based compensation expense consists of the following:

| | Three Months Ended 30 September | | | | Six Months Ended 30 September | | | | |
|--------------------------------|------------------------------------|----|------|----|----------------------------------|----|------|-----|--|
| (Millions of US dollars) | 2024 | | 2023 | | 2024 | | 2023 | | |
| Liability Awards | \$ 5.3 | \$ | 1.8 | \$ | 3.4 | \$ | 5 | 5.9 | |
| Equity Awards | 8.0 | | 6.2 | | 12.3 | | 12 | 2.3 | |
| Total stock-based compensation | \$ 13.3 | \$ | 8.0 | \$ | 15.7 | \$ | 18 | 3.2 | |

As of 30 September 2024, the unrecorded future stock-based compensation expense related to outstanding equity awards was US\$39.9 million and will be recognized over an estimated weighted average amortization period of 2.0 years.

11. Capital Management

In November 2023, the Company announced a share buyback program to acquire up to US\$250 million of its outstanding shares through October 2024. In June 2024, the Company announced a US\$50 million increase to this share buyback program to acquire up to US\$300 million of its outstanding shares.

For the six months ended 30 September 2024, the Company repurchased 4.5 million shares under its share buyback program for US\$149.9 million at an average per share price of US\$33.48. This completes the share buyback program announced.

In November 2024, the board of directors approved and authorized a new share buyback plan, for an aggregate amount up to US\$300 million through 31 October 2025.

12. Segment Information

The Company reports its operating segment information in the format that the operating segment information is available to and evaluated by the Chief Operating Decision Maker. The North America Fiber Cement segment manufactures fiber cement interior linings, exterior siding products and related accessories in the United States; these products are sold in the United States and Canada. The Asia Pacific Fiber Cement segment includes fiber cement products manufactured in Australia and the Philippines (through August 2024), and sold in Australia, New Zealand and the Philippines. The Europe Building Products segment includes fiber gypsum product manufactured in Europe, and fiber cement product manufactured in the United States that is sold in Europe. The Research and Development segment represents the cost incurred by the research and development centers. General Corporate primarily consist of *Asbestos adjustments*, officer and employee compensation and related benefits, professional and legal fees, administrative costs and rental expense on the Company's corporate offices. The Company does not report net interest expense for each segment as the segments are not held directly accountable for interest expense.

Operating Segments

The following is the Company's operating segment information:

| | Net Sales | | | | | | | | | |
|----------------------------|-----------|------------------------------------|----|-------|----|----------------------------------|----|---------|--|--|
| | | Three Months Ended 30 September | | | | Six Months Ended 30 September | | | | |
| (Millions of US dollars) | | 2024 | | 2023 | | 2024 | | 2023 | | |
| North America Fiber Cement | \$ | 695.8 | \$ | 734.4 | \$ | 1,425.1 | \$ | 1,429.2 | | |
| Asia Pacific Fiber Cement | | 148.4 | | 147.4 | | 283.7 | | 287.5 | | |
| Europe Building Products | | 116.6 | | 117.0 | | 243.9 | | 236.4 | | |
| Total | \$ | 960.8 | \$ | 998.8 | \$ | 1,952.7 | \$ | 1,953.1 | | |

| | Operating Income | | | | | | | | | |
|----------------------------|------------------|------------------------------------|----|--------|----|----------------------------------|----|--------|--|--|
| | | Three Months Ended 30 September | | | | Six Months Ended 30 September | | | | |
| (Millions of US dollars) | | 2024 | | 2023 | | 2024 | | 2023 | | |
| North America Fiber Cement | \$ | 201.9 | \$ | 232.7 | \$ | 429.2 | \$ | 450.3 | | |
| Asia Pacific Fiber Cement | | (8.0) | | 44.4 | | 33.2 | | 90.9 | | |
| Europe Building Products | | 8.9 | | 12.5 | | 21.1 | | 24.3 | | |
| Research and Development | | (9.3) | | (9.1) | | (18.8) | | (17.4) | | |
| Segments total | | 193.5 | | 280.5 | | 464.7 | | 548.1 | | |
| General Corporate | | (41.2) | | (57.1) | | (77.0) | | (90.8) | | |
| Total | \$ | 152.3 | \$ | 223.4 | \$ | 387.7 | \$ | 457.3 | | |

James Hardie Industries plc Notes to Condensed Consolidated Financial Statements (continued)

| | Depreciation and Amortization | | | | | | | | | |
|----------------------------|-------------------------------|------------------------------------|----|------|----|-------------------|----|------|--|--|
| | | Three Months Ended 30 September | | | | Six M Ended 30 | | | | |
| (Millions of US dollars) | | 2024 | | 2023 | | 2024 | | 2023 | | |
| North America Fiber Cement | \$ | 38.2 | \$ | 33.4 | \$ | 74.3 | \$ | 66.1 | | |
| Asia Pacific Fiber Cement | | 4.7 | | 4.2 | | 9.5 | | 8.3 | | |
| Europe Building Products | | 8.1 | | 6.9 | | 15.6 | | 13.9 | | |
| Research and Development | | 0.7 | | 0.4 | | 1.4 | | 1.0 | | |
| General Corporate | | 0.2 | | 0.6 | | 0.9 | | 1.1 | | |
| Total | \$ | 51.9 | \$ | 45.5 | \$ | 101.7 | \$ | 90.4 | | |

| | Research and Development Expenses | | | | | | | | | |
|----------------------------|-----------------------------------|------------------------------------|----|------|----|----------------------------------|----|------|--|--|
| | | Three Months Ended 30 September | | | | Six Months Ended 30 September | | | | |
| (Millions of US dollars) | | 2024 | | 2023 | | 2024 | | 2023 | | |
| North America Fiber Cement | \$ | 3.0 | \$ | 1.8 | \$ | 5.3 | \$ | 3.8 | | |
| Asia Pacific Fiber Cement | | 0.3 | | 0.3 | | 0.6 | | 0.6 | | |
| Europe Building Products | | 0.8 | | 0.8 | | 1.1 | | 1.5 | | |
| Research and Development | | 8.7 | | 8.2 | | 17.6 | | 15.9 | | |
| Total | \$ | 12.8 | \$ | 11.1 | \$ | 24.6 | \$ | 21.8 | | |

13. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss consists of the following at 30 September 2024:

| (Millions of US dollars) | Cash Flow Hedges | | Pension Actuarial Gain | | Foreign Currency Translation Adjustments | Total |
|--|---------------------|-------|------------------------------|----|---|--------|
| Balance at 31 March 2024 | \$ | 0.2 | \$ 1.3 | \$ | (69.8) \$ | (68.3) |
| Other comprehensive (loss) income | | (0.1) | | | 10.3 | 10.2 |
| Reclassification to Restructuring expenses | | — | — | | 8.3 | 8.3 |
| Reclassification to Selling, general and administrative expenses | | | _ | | 0.2 | 0.2 |
| Balance at 30 September 2024 | \$ | 0.1 | \$ 1.3 | \$ | (51.0) \$ | (49.6) |